-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 15, Sino Biopharmaceuticals issued a positive profit forecast.
It is expected that the profit attributable to the parent company in 2021 will increase by more than 4 times year-on-year to more than RMB 14 billion (2.
771 billion in 2020).
Due to: (1) the satisfactory performance of the main business, the increase in the proportion of sales of new products and products with high gross profit margin during the year, the overall revenue and gross profit margin increased significantly year-on-year; Profits and losses of associates and joint ventures increased significantly year-on-year
.
From: Corporate Announcement
Sino Biopharmaceutical holds a 15.
03% stake in Kexing Zhongwei, and Kexing's new crown vaccine Kerroff has contributed a lot of income
.
Judging from the previous 2021 semi-annual report data, Sino Biopharmaceutical's net profit in the first half of 2021 was 8.
Sino Biopharmaceutical holds a 15.
China Biopharma's New Drug Application Trends in the Past Five Years
From: Insight Database Project Progress Module (http://db.
dxy.
cn/v5/home/)
*Only screen all new chemical drugs + new biological products + biosimilar projects, the following are similar
Distribution of research and development stages of new biopharmaceutical projects in China
From: Insight Database Enterprise Analysis Module (http://db.
dxy.
cn/v5/home/)
In terms of enterprise distribution, Chia Tai Tianqing is the main force among the subsidiaries of China Biopharmaceuticals
.
In terms of component categories, chemical drugs are the absolute main force, followed by monoclonal antibodies.
Visualization Analysis of China Biopharmaceutical New Drug Projects (Insight)
From: Insight Database Project Progress Module (http://db.
So far in 2022, Sino Biopharmaceuticals has filed 1 category 1 new drug for listing, which is ebeggravstim α injection introduced from Yiyi Bio (click here to view the acceptance number); another 10 clinical-stage projects have made new progress , see the figure below:
From: Insight Database Project Progress Module (http://db.
